IP Library Granted Patent US 7,833,983
Granted Patent B2
US 7,833,983 · App. 10/551,636 · Granted Nov 16, 2010

Analytical method and kit thereof

Assignee: Phadia, AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,833,983
App. No.
10/551,636
Granted
Nov 16, 2010
Kind
B2
Abstract

The present invention relates to a peptide comprising a symmetrical dimethylated arginine, and constitute an immunologic determinant of antibodies present in sera from patients with systemic lupus erythematosus (SLE), and wherein the methylation is a prerequisite for reacting with said antibodies. The invention also relates to the use of said peptide for diagnosis of SLE and the differentiation between SLE and MCTD.

Claims (14)

1. A peptide consisting of the amino acid sequence

AARGsdRGRGMGRGNIF (SEQ ID NO: 1)

wherein the amino acid sdR is symmetric dimethylated arginine having the structure

and wherein the peptide is able to react with antibodies which are presented in sera from patients with systemic lupus erythematosus (SLE).

2. A method of diagnosing systemic lupus erythematosus (SLE), comprising contacting sera of a patient with a composition comprising the peptide of claim 1 .

3. The method according to claim 2 , wherein the diagnosis is differential diagnosis to distinguish between SLE patients and patients with mixed connective tissue disease (MCTD).

4. The method according to claim 2 , wherein the diagnosis is an in vitro diagnosis of SLE.

5. The method according to claim 2 , wherein said composition is used for differentiation between SLE and mixed connective tissue disease (MCTD).

6. A peptide comprising multimers of the peptide of claim 1 .

7. A kit for detection of antibodies, comprising the peptide of Claim 1 .

8. A kit according to claim 7 , wherein said peptide is used for in vitro diagnosis of SLE.

9. A kit according to claim 7 , wherein said peptide is used for differential diagnosis to distinguish between SLE and mixed connective tissue disease (MCTD).

10. A method for monitoring a disease activity comprising repeated testing to follow the titer of antibodies able to react with the peptide according to claim 1 in order to monitor the effect of treatment or the disease activity, wherein the disease is SLE.

11. The method according to claim 10 , wherein said disease is dsDNA negative SLE.

Assignments (2)
CHANGE OF NAME Recorded Oct 10, 2006
From: PHARMACIA DIAGNOSTICS AB
To: PHADIA AB
Reel/Frame 018375/0446 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2006
From: MAHLER, MICHAEL
To: PHARMACIA DIAGNOSTICS AB
Reel/Frame 017810/0711 →
Priority Claims (1)
SE 0300958 · Apr 2, 2003 · national
Continuity (1)
Related Publication 20060240477A1 · Oct 26, 2006